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Abstract
Pneumocystis jirovecii (carinii) pneumonia (PJP) is a major cause of disease in immunocompromised individuals. However, until recently no
reliable and speciﬁc serological parameters for the diagnosis of PJP have been available. (1 ﬁ 3)-b-D-Glucan (BG) is a cell wall compo-
nent of P. jirovecii and of various other fungi. Data from the past few years have pointed to serum measurement of BG as a promising
new tool for the diagnosis of PJP. We therefore conducted a retrospective study on 50 patients with PJP and 50 immunocompromised
control patients to evaluate the diagnostic performance of serum BG measurement. Our results show an excellent diagnostic perfor-
mance with a sensitivity of 98.0% and a speciﬁcity of 94%. While the positive predictive value was only 64.7%, the negative predictive
value was 99.8% and therefore a negative BG result almost rules out PJP. BG levels were already strongly elevated in an average of
5 days and up to 21 days before microbiological diagnosis demonstrating that the diagnosis could have been conﬁrmed earlier. BG levels
at diagnosis and maximum BG levels during follow-up did not correlate with the outcome of patients or with the P. jirovecii burden in
the lung as detected by Real-Time PCR. Therefore, absolute BG levels seem to be of no prognostic value. Altogether, BG is a reliable
parameter for the diagnosis of PJP and could be used as a preliminary test for patients at risk before a bronchoalveolar lavage is per-
formed.
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Introduction
Pneumocystis jirovecii (carinii) pneumonia (PJP) is a major cause
of mortality in immunocompromised individuals. Therefore,
early diagnosis and therapy is vital.
Currently, the laboratory reference standard for the
detection of P. jirovecii is staining of the organism with mono-
clonal antibodies, followed by immunoﬂuorescence micro-
scopy in bronchoalveolar lavage (BAL) ﬂuid. Together with a
compatible clinical presentation and conﬁrmation by com-
puted tomography, this allows the diagnosis to be made.
However, diagnosis of PJP is hampered by the fact that the
performance of BAL is not always possible, owing to the lim-
ited respiratory function of some patients. Furthermore,
detection of P. jirovecii is not necessarily equivalent to infec-
tion, because of the existence of clinically insigniﬁcant
P. jirovecii colonization [1,2]. Until recently, no reliable sero-
logical parameters for the diagnosis of PJP were available.
(1 ﬁ 3)-b-D-Glucan (BG) is a cell wall component of
P. jirovecii and of various other fungi. During the course of an
invasive infection, BG is released into the serum. Data
collected over recent years have shown that serum BG mea-
surement might be a powerful new tool for the diagnosis of
PJP (Table 1). However, in these studies various test systems
with different characteristics have been used, and direct
comparison of the reported observations is not possible.
The Fungitell assay is a Limulus amebocyte lysate-based test
for the measurement of BG. So far, there have been only
two retrospective studies with sizeable numbers of patients
(20 and 28, respectively) and a relevant control group that
have used the Fungitell assay for the diagnosis of PJP [3,4].
Furthermore, information on the prognostic beneﬁt of BG
measurement is limited, and results are inconclusive [5–8].
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We therefore conducted a retrospective study on 50
patients with PJP and 50 control patients to evaluate the
diagnostic performance of serum BG measurement, with a
special focus on its prognostic relevance.
Materials and Methods
PJP patients
During the study period (January 2002 to January 2010),
2287 BAL samples from 1488 patients were examined for
P. jirovecii (2158 by immunostaining; 129 by nested PCR).
Two hundred and sixty-ﬁve analyses on samples from 150
patients (10.1%) gave positive results. Seventy-eight of these
P. jirovecii-positive patients had an archived serum sample
around the day of the bronchoscopy (±7 days). Fifty of them
(34 with positive immunostaining and positive PCR ﬁndings,
12 with positive immunostaining only and four with positive
PCR ﬁndings only) showed a clinical picture typical of PJP,
and were not subject to any of the exclusion criteria. Clinical
presentation was considered to be typical if pulmonary inﬁl-
trates compatible with PJP were present and if at least four
of the following criteria were met: existing immunosuppres-
sion, fever, dyspnoea, cough, elevated lactate dehydrogenase
(LDH) level and hypoxia. Exclusion criteria were culture of any
fungus from relevant materials, positive serum galactomannan
assay (Platelia Aspergillus EIA; Bio-Rad Laboratories, GmbH,
Munich, Germany) or positive serum Candida antigen assay
(Cand-Tec; Ramco Laboratories, Inc., Stafford, TX, USA).
Colonization with yeast or superﬁcial candidiasis was not
considered to be an exclusion criterion, because BG levels
are not normally elevated in those patients [9,10].
Quantitative real-time PCR of the four patients who
tested positive in PCR only showed very high copy numbers
(two with >106 copies/mL; one with 105–106 copies/mL; and
one with 104–105 copies/mL). Given the clinical ﬁndings, it
seemed unlikely that PCR detected only colonization. These
50 patients were included in the PJP group (Table 2). Further
analysis of the PJP group showed that 45 patients were
admitted to the hospital with acute PJP. The remaining ﬁve
patients had already been in hospital when they developed
PJP. The reason for their initial admittance was intestinal
graft-versus-host disease after haematopoietic stem cell
transplantation, chemotherapy for B-cell non-Hodgkin lym-
phoma, methotrexate and corticosteroid therapy for pem-
phigus vulgaris, and heart transplantation (two patients). All
50 patients were hospitalized after diagnosis of PJP for intra-
venous antibiotic treatment.
Endpoints of the analysis were death from all causes or
discharge. The median length of hospitalization was 25 daysT
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(interquartile range (IQR) 16–34). The median duration from
admission to microbiological diagnosis was 5 days (IQR 2–
10). The median duration from microbiological diagnosis to
discharge was 21 days (IQR 12–29). Survivors (n = 35) had a
median follow-up period of 29 days (IQR 22–43).
Controls
The control group consisted of all patients, between Decem-
ber 2008 and January 2010, whose BAL ﬂuids were negative
for P. jirovecii in immunostaining (n = 312) and for whom an
archived serum sample taken around the day of the bron-
choscopy (±7 days) existed (n = 86). Only control patients
who were immunocompromised and who had a suspected
infectious respiratory disease (pulmonary inﬁltrates, clinical
symptoms, elevated leukocyte count and/or elevated C-reac-
tive protein (CRP)) were included. Exclusion criteria were
identical to those for the study group. The collection was
stopped when 50 patients had been included (Table 2).
Collection of clinical data
Patient demographics and clinical characteristics were col-
lected, including age, sex, underlying disease, type of immuno-
suppression, CRP level, leukocyte count, CD4 cell count, LDH
level, PaO2, albumin level, creatinine level, alanine transaminase
level, aspartate transaminase level, c-glutamyltransferase level,
PJP prophylaxis and microbiological results. The therapy was
reviewed for possible confounding factors for BG measure-
ment, including intravenous immunoglobulin and albumin.
Serum collection and BG measurement
The sera retrospectively tested were drawn around the time
of microbiological diagnosis and, if available, until discharge.
One or more subsequent sera were available from 34 of the
50 P. jirovecii-positive patients. Serum samples were originally
taken for various microbiological analyses other than BG, and
were routinely frozen at )80C. The use of these sera was
approved by the local ethics committee (application num-
ber 105/09). Serum samples were examined for the presence
of BG with the Fungitell assay (Associates of Cape Cod, Inc.,
East Falmouth, MA, USA). The test was performed at our own
institution, according to the manufacturer’s recommendations.
Each serum was tested in duplicate. The persons who tested
the sera were not blinded. Samples with BG levels above
500 pg/mL were diluted and retested. BG levels below 31 pg/
mL (lower validation limit) were calculated by extrapolation.
Indirect immunoﬂuorescence staining
Monoclonal antibody staining for P. jirovecii was performed with
the DETECT IF test (Axis Shield Diagnostics Limited, Dundee,
UK) according to the manufacturer’s recommendations.
Touchdown PCR
DNA from BAL ﬂuids was isolated by proteinase K digestion
followed by phenol–chloroform extraction, and serum DNA
was extracted with the QIAmp DNA Mini Kit (Qiagen
GmbH, Hilden, Germany). Touchdown PCR was performed
as previously described [11]. All ampliﬁcation products were
TABLE 2. Baseline characteristics
of the study populations and main
results
PJP group Control group
No. of patients 50 50
Mean age (years) (range) 51 (4–74) 56.5 (6–83)
Sex (male/female) 33/17 25/25
Underlying disease (no. of patients)
HIV 17 1
Haematological malignancies 10 18
OTX (KTX/HTX/LTX) 11 (6/5/0) 6 (2/0/4)
Immunological disorder 5 10
Haematological malignancies + HSCT 4 12
Solid tumours 3 3
Mean CD4+ T-cells of HIV patients
(cells/lL) (range)
37 (3–139) 120
Median BGDIAGNOSIS (pg/mL) (IQR, range) 823 (461–4870, 31–38 400) 27 (8–48, 8–273)
Median BGMAX (pg/mL) (IQR, range) 1153 (461–7444, 31–38 400) –
Interpretation of BG test
Positive (>85 pg/mL) 49 3
Negative (£85 pg/mL) 1 47
Sensitivity (%) (95% CI) 98.0 (89.3–99.7)
Speciﬁcity (%) (95% CI) 94.0 (83.4–98.7)
Positive predictive value (%) (95% CI) 64.7 (36.6–86.8)
Negative predictive value (%) (95% CI) 99.8 (95.2–99.0)
Likelihood ratio, positive (95% CI) 16.33 (15.1–17.7)
Likelihood ratio, negative (95% CI) 0.021 (0.002–0.2)
BG, (1 ﬁ 3)-b-D-glucan; HIV, human immunodeﬁciency virus; HSCT, haematopoietic stem cell transplantation; HTX,
heart transplantation; IQR, interquartile range; KTX, kidney transplantation; LTX, lung transplantation; OTX, organ
transplantation; PJP, Pneumocystis jirovecii pneumonia.
The PJP group contains a considerably higher number of HIV-positive patients than the control group. This is because
the suspected diagnosis of PJP proved to be true in most cases, and therefore HIV patients with a negative result for
P. jirovecii-speciﬁc immunoﬂuorescence staining were rare.
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sequenced and conﬁrmed to be part of the P. jirovecii mito-
chondrial large-subunit rRNA gene.
Real-time PCR
On the basis of a previously published protocol [12], quanti-
tative real-time PCR was performed on DNA preparations
from serum and BAL samples. Brieﬂy, 5-lL aliquots were
used as template DNA for subsequent PCR testing on a Light-
Cycler (Roche Diagnostics, Mannheim, Germany). Samples
positive for the speciﬁc amplicons were identiﬁed by the PCR
instrument at the cycle number where the individual ﬂuores-
cence value exceeded that measured for background. The
quantitative interpretation of the results was assisted by a set
of external standards that were tested in parallel.
Statistical methods
Statistical analysis was performed using SPSS, version 17.0.
Unless otherwise stated, BG levels are expressed as median
concentration with IQR. For comparison of variables, Pearson’s
chi-square test, the Mann–Whitney U-test or the Kruskal–Wallis
test was used. Differences were considered signiﬁcant for
p <0.05. Receiver operating characteristic (ROC) analysis was
carried out using MedCalc, version 10.0. The optimal BG cut-off
was determined with the maximum Youden index.
Results
BAL samples from 1488 patients were examined between
January 2002 and January 2010 for the presence of P. jirovecii.
Fifty P. jirovecii-positive patients met the clinical inclusion cri-
teria and were enrolled in the PJP group. Between Decem-
ber 2008 and January 2010, examination for P. jirovecii in BAL
ﬂuid gave negative ﬁndings in 312 patients. Of these, 50 im-
munosuppressed patients with pneumonia were selected as
controls (Table 2).
Serum BG measurement as an indicator for P. jirovecii
pneumonia
Because the BG cut-off recommended by the manufacturer
(80 pg/mL) was originally designed for the diagnosis of inva-
sive fungal infections other than PJP, we ﬁrst performed a
ROC analysis on our data. According to the ROC analysis,
the optimal BG cut-off for the diagnosis of PJP, determined
with the maximum Youden index, would be >85 pg/mL. The
area under the ROC curve was 0.987 (95% CI 0.941–0.998;
p 0.0001). With this optimized cut-off, 49 of 50 patients in
the PJP group tested positive for serum BG at the time of
diagnosis. The negative patient had a serum BG level of
31 pg/mL. The median BG concentration in the PJP group at
the time of diagnosis was 823 pg/mL (IQR 461–4870,
range 31–38 400). The median highest BG level during hospi-
talization was 1153 pg/mL (IQR 461–7444, range 31–38 400).
In the control group, three patients tested positive (Table 3)
and 47 patients were negative for serum BG. The median BG
concentration in the control group was 27 pg/mL (IQR 8–
48), ranging from non-detectable to 273 pg/mL. The differ-
ence in BG levels between the PJP group and the control
group was highly signiﬁcant (p <0.001). On the basis of these
results, the sensitivity of the BG assay for the diagnosis of PJP
TABLE 3. Characteristics of false-negative and false-positive patients
False-negative
patient
False-positive
patient 1
False-positive
patient 2
False-positive
patient 3
Age (years) 37 70 73 11
Sex Female Female Male Female
Underlying disease Arthritis under
corticosteroid therapy
AML with HSCT AML with HSCT ALL
Detection of Pneumocystis jirovecii IFS + PCR Negative Negative Negative
BGDIAGNOSIS 31 273 177 145
Confounding factors None None Dialysis None
Other pathogen in BAL ﬂuid No No Pseudomonas aeruginosa RSV
Bacteraemia/viraemia CMV No Pseudomonas aeruginosa No
Mucositis No No No Yes
Creatinine (mg/L) 0.23 2.70 2.92 0.85
ASTDIAGNOSIS (U/L) Not tested 47 35 554
ALTDIAGNOSIS (U/l) Not tested 58 20 199
GGTDIAGNOSIS (U/L) Not tested 218 Not tested 124
ALL, acute lymphoblastic leukaemia; ALT, alanine transaminase; AML, acute myeloid leukaemia; AST, aspartate transaminase; BAL, bronchoalveolar lavage; BG, (1 ﬁ 3)-b-D-
glucan; CMV, cytomegalovirus; GGT, c-glutamyltransferase; HSCT, haematopoietic stem cell transplantation; IFS, speciﬁc immunoﬂuorescence staining; RSV, respiratory syncy-
tial virus.
The false-negative patient had a proven PJP by standard criteria. Despite high-dose trimethoprim–sulphamethoxazole therapy, the condition of the patient deteriorated, and
she died 6 days after admission to the intensive-care unit. In the post-mortem lung biopsy specimen, P. jirovecii could still be detected by immunostaining. The reason for the
negative BG result is unclear. False-positive patient 2 had a positive blood culture for Pseudomonas aeruginosa 11 days after the serum for BG testing was drawn. However,
blood cultures taken on the day of serum sampling and 1 day and 2 days after serum sampling were negative for Pseudomonas aeruginosa. Although Pseudomonas aeruginosa is
described as a source of false-positive BG results [25], it seems unlikely that, in this patient, the delayed bacteraemia was responsible for the elevated BG level. Another pos-
sible confounding factor in this patient was dialysis. However, the dialysis membranes used at our hospital were tested, and dialysis had no signiﬁcant effect on BG levels.
False-positive patient 3 had a mucositis, and it is possible that BG from the gastrointestinal tract was entering the bloodstream.
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was 98.0% (95% CI 89.3–99.7%) and the speciﬁcity was 94.0%
(95% CI 83.4–98.7%). The positive predictive value and nega-
tive predictive value were 64.7% (95% CI 36.6–86.8%) and
99.8% (95% CI 95.2–99.0%), respectively.
BG measurement for earlier conﬁrmation of diagnosis
Sera from 36 patients were available in the 3 weeks prior to
diagnosis. The median time of serum sampling before diagno-
sis was 7 days. Thirty-four of these patients (94%) already
had highly elevated BG levels (792 pg/mL, IQR 316–3557,
range 122–14 220) at an average of 5 days (IQR 1.8–9.3,
range 1–21) before microbiological diagnosis. As expected,
the shorter the time interval between sample date and diag-
nosis date, the higher the serum BG levels. Within the last
10 days before diagnosis, the median BG level was 831 pg/
mL (n = 26, IQR 541–4202, range 122–14 220). In the per-
iod between day 10 and day 21 before diagnosis, the median
BG concentration was 269 pg/mL (n = 8, IQR 154–656,
range 127–6460). For the two patients who had negative
results, serum samples were drawn at day 19 and day 20
before diagnosis.
Correlation of BG levels with clinical outcome
To determine the prognostic value of BG levels at diagnosis
(BGDIAGNOSIS) and of maximum BG levels during hospitaliza-
tion (BGMAX), the patients were divided into groups based
on the median, the tertile and the quartile BG levels. The
cumulative mortality of the respective groups was then com-
pared. However, no statistically signiﬁcant differences in
mortality were found between the groups (Table 4).
Because the survivor group was very diverse with respect
to clinical course, we subdivided them into patients with
rapid improvement after the initiation of therapy (n = 18)
and patients with a severe disease course (n = 17). Patients
were considered to have a severe disease course if there
was no clinical improvement within the ﬁrst 7 days of ther-
apy, if treatment in an intensive-care unit or mechanical ven-
tilation was necessary, if therapy needed to be continued
after 21 days, or if treatment failure was suspected and the
antifungal regimen had to be changed. Again, the patients
were divided on the basis of the median, tertile and quartile
BG levels, and the percentages of patients in the groups with
a different clinical course were compared. Subdivision of the
study population on the basis of clinical course also did not
result in signiﬁcant differences (data not shown).
It has been reported that a number of confounding factors
exist that are capable of causing false-positive BG results.
TABLE 4. Mortality of Pneumocystis jirovecii (carinii) pneu-
monia patients stratiﬁed by median, tertile and quartile
(1 ﬁ 3)-b-D-glucan (BG) levels
1st 2nd 3rd 4th p-value
BG measurement at microbiological diagnosis
Mortality, median (%) 28.0 28.0 – – 1.000
Mortality, tertiles (%) 31.3 11.8 41.2 – 0.125
Mortality, quartiles (%) 41.7 15.4 33.3 23.1 0.482
Maximum BG levels during hospitalization
Mortality, median (%) 28.0 28.0 – – 1.000
Mortality, tertiles (%) 31.3 23.5 29.4 – 0.874
Mortality, quartiles (%) 41.7 15.4 30.8 25.0 0.524
For determination of the prognostic value of BG levels, the patients were
divided into groups based on the median, tertile and quartile BG levels. This
was performed for the BG levels at diagnosis and for the maximum BG levels
during hospitalization. The mortality of the respective groups was then com-
pared with Pearson’s chi-square test. There was no signiﬁcant difference in mor-
tality, and therefore absolute BG levels do not predict the outcome.
TABLE 5. Clinical characteristics of patients with Pneumocystis jirovecii pneumonia
HIV
Haematological
malignancies
Organ
transplantation
Immunological
disorders
Haematological
malignancies + HSCT
Solid
tumours
Number of patients 17 10 11 5 4 3
Mean age (years) (range) 41 (27–59) 58 (4–74) 62 (39–68) 71 (38–76) 65 (26–67) 55 (33–58)
Sex (male/female) 11/6 7/3 6/5 4/1 2/2 3/0
Median length of hospitalization (days) 28 25 32 20 13 16
BGDIAGNOSIS (pg/mL) (range) 778 (177–15 430) 554 (142–14 220) 2928 (481–38 400) 507 (31–4820) 662 (199–3300) 628 (527–7300)
BGMAX (pg/mL) (range) 929 (180–31 360) 554 (146–25 600) 9730 (481–38 400) 507 (31–4820) 1349 (199–300) 628 (527–9000)
Median time periodBG-DIAGNOSIS
(days) (range)
6 (1–19) 8 (1–13) 2 (1–9) 2 10 (3–21) 6.5 (1–12)
CRP (mg/L) (range) 17 (2–227) 71 (6–331) 32 (6–228) 41 (24–425) 106 (73–188) 17 (9–36)
Leukocyte count (cells/lL) (range) 5.60 (1.7–12.9) 6.50 (3–98.9) 9.55 (3.6–18.3) 10.90 (2.2–14.4) 4.35 (1.5–12.5) 8.00 (4.3–12.0)
CD4+ cells (cells/lL) (range) 37 (3–139) 151 478 (348–677) 456 (129–782) – –
LDH (U/L) (range) 374 (173–1186) 499 (248–1493) 555 (354–970) 285 (162–633) 240 (177–714) 582 (213–687)
PaO2 (mmHg) (range) 49.70 (40–86) 59.10 (27–72) 69.85 (21–88) 71.40 (24–76) 54.45 (50–59) 58.00
CreatinineDIAGNOSIS (mg/dL) (range) 0.70 (0.46–1.10) 0.80 (0.25–1.20) 1.70 (0.50–3.00) 1.20 (0.23–2.95) 1.13 (0.57–1.70) 0.79 (0.75–0.90)
CreatinineMAX (mg/dL) (range) 0.90 (0.66–3.00) 1.02 (0.25–2.1) 2.22 (0.7–4.3) 1.27 (0.23–2.95) 1.39 (0.60–2.91) 0.90 (0.79–1.20)
AST (U/L) (range) 44 (22–368) 61 (18–3002) 58 (25–406) 33 (16–66) 40 (18–61) 36 –
ALT (U/L) (range) 31 (12–295) 59 (23–964) 46 (7–274) 32 (22–41) 26 (23–100) 43 (32–54)
GGT (U/L) (range) 64 (14–421) 164 (25–347) 46 (21–530) 66 (58–162) 112 (25–279) 81 (65–138)
ALT, alanine transaminase; AST, aspartate transaminase; BG, (1 ﬁ 3)-b-D-glucan; CRP, C-reactive protein; GGT, c-glutamyltransferase; HIV, human immunodeﬁciency virus;
HSCT, haematopoietic stem cell transplantation; LDH, lactate dehydrogenase; time periodBG-DIAGNOSIS, time period from ﬁrst positive BG measurements to microbiological
conﬁrmation of diagnosis
Organ transplant recipients had signiﬁcantly higher BG levels and creatinine levels than the other patients.
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The major candidates are administration of fractionated
blood products (e.g. immunoglobulins and albumin) and hae-
modialysis with certain cellulose membranes [13–18]. We
reviewed the treatment protocols of every patient to identify
a possible role of such confounding factors that might distort
the analysis. None of our patients had been exposed to any
of these confounding factors prior to the day on which the
ﬁrst serum sample was taken, but during the time of their
treatment, 12 patients were given immunoglobulins and/or
albumin. Surprisingly, median BGMAX did not change when
patients with possible confounding factors were excluded
(n = 38; BGMAX 1153 pg/mL, IQR 461–7040, range 31–
38 400), and there was no signiﬁcant difference in the cumu-
lative mortality between patients of the different groups.
Correlation of BG levels with clinical characteristics
(Table 5)
There was no correlation between age, CRP level, leukocyte
count, LDH level, PO2, albumin, alanine transaminase level,
aspartate transaminase level, c-glutamyltransferase level and
BG level. However, high BG levels correlated with high
creatinine levels (p 0.012). In contrast to a previous study
[7], our data showed no signiﬁcant difference in BG levels
between human immunodeﬁciency virus (HIV)-positive
patients and non-HIV patients. The group of organ transplant
recipients, however, showed signiﬁcantly higher BGMAX levels
than the remainder of the patients (pDIAGNOSIS 0.063;
pMAX 0.022). We further stratiﬁed this group according to the
organ that had been transplanted. The group consisted of six
kidney and ﬁve heart transplant recipients. There was a ten-
dency for there to be higher BG levels in kidney transplant
recipients than in heart transplant recipients (BGDIAGNOSIS
2928 pg/mL, IQR 736–13 208 for kidney transplant recipients
vs. 897 pg/mL, IQR 669–21 710 for heart transplant recipi-
ents; BGMAX 13 415 pg/mL, IQR 1543–19 455 for kidney
transplant recipients vs. 5020 pg/mL, IQR 689–22 430 for
heart transplant recipients), but the difference was not statisti-
cally signiﬁcant (pDIAGNOSIS 0.93; pMAX 0.54). Inclusion of
other clinical parameters in the analysis showed that organ
transplant recipients had higher creatinine levels (p 0.003) and
LDH levels (p 0.021) than the other patients.
Correlation of BG levels with DNA levels in BAL ﬂuid and
sera as detected by PCR
To evaluate whether the P. jirovecii burden in the lung corre-
lated with the BG levels measured in the serum, available
BAL ﬂuids (n = 38) were tested for P. jirovecii DNA by
real-time PCR. P. jirovecii DNA could be detected in all BAL
samples (>106 copies/mL in 21 patients, 105–106 copies/mL
in six patients, 104–105 copies/mL in ﬁve patients,
103–104 copies/mL in four patients, and 102–103 copies/mL
in two patients). However, there was no signiﬁcant correla-
tion between the quantitative PCR results and serum BG
levels (pRealTimePCR 0.766).
Furthermore, sera of all patients (n = 50) at the time of
diagnosis as well as at the time of maximum BG levels were
tested for P. jirovecii DNA by touchdown PCR, and selected
sera were additionally tested by quantitative real-time PCR.
Each PCR system could detect P. jirovecii DNA in a total of
three sera (sensitivity of 6%). Two of these sera were positive
in both PCR systems, whereas the third serum sample tested
positive in one system but not in the other. Neither the levels
of BG nor the outcome correlated with serum PCR positivity.
Discussion
We have conducted a retrospective study with the Fungitell
assay to evaluate the usefulness of serum BG measurement
for the diagnosis of PJP. Our results show an excellent diag-
nostic performance, with a sensitivity of 98% and a speciﬁcity
of 94%, and thereby conﬁrm the data of previous studies.
The positive predictive value was only 64.7%, possibly
because BG is inﬂuenced by a number of as yet unknown
confounding factors, and because BG is elevated not only in
PJP but also in most other invasive fungal infections. As a
consequence, BG levels alone cannot prove the existence of
PJP, and they must not be interpreted without considering
the clinical ﬁndings. However, with a negative predictive
value of 99.8%, a BG level £85 pg/mL almost rules out PJP,
and this could be extremely helpful in patients who cannot
undergo bronchoscopy or in patients where the clinical sus-
picion of PJP is low.
Usually, there is a signiﬁcant delay between the onset of
symptoms and the diagnosis of PJP. Median intervals are
reported to be 21–28 days in HIV-positive patients [19]. In
our study, BG levels were already strongly elevated at an
average of 5 days before microbiological diagnosis. For the
majority of patients, there was only one pre-existing serum
available, and the median of serum sampling was at day 7.
Therefore, it is unclear exactly when BG levels exceeded the
cut-off. The average time-span of 5 days between BG positiv-
ity and microbiological diagnosis is most likely an underesti-
mation caused by a lack of samples dating further back. So
far, our data suggest that BG levels are elevated up to
21 days before microbiological diagnosis, and timely BG mea-
surement could allow for the earlier initiation of effective
treatment (Fig. 1).
Data on the correlation between BG levels and the out-
comes of patients are limited, and the results are inconclu-
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sive. Two studies reported that high levels of BG are associ-
ated with poor prognosis [5,6], whereas two other studies
could not ﬁnd a signiﬁcant difference in BG levels between
survivors and non-survivors [7,8]. The analysis of our data
showed no signiﬁcant difference in the mortality or severity
of PJP between patients with high and those with low BG
levels. These ﬁndings are supported by our observation that
there was no correlation between pulmonary P. jirovecii bur-
den, as detected by quantitative real-time PCR, and serum
BG levels. However, the results of real-time PCR on BAL
ﬂuids are strongly dependent on the quality of the material,
and we cannot rule out the possibility that suboptimal sam-
pling affected the data quality.
Although the absolute BG level at diagnosis and the maxi-
mum BG level during hospitalization do not seem to have
prognostic relevance, this might be different for BG kinetics.
It has been shown in individual cases that a favourable out-
come can be paralleled by decreasing BG levels [20], an
observation that is supported by our own experience. How-
ever, further work is clearly necessary to conﬁrm these
reports in larger series.
The severity and mortality of PJP, as well as BG levels, have
been reported to be lower in HIV-positive patients than in non-
HIV patients [19]. We did not observe a signiﬁcant difference in
the BG levels between those two groups of patients. However,
subgroup analysis of patients with different underlying diseases
showed signiﬁcantly higher BG levels in organ transplant recipi-
ents. At the same time, organ transplant recipients and patients
with high BG levels in general showed higher creatinine levels,
whereas liver enzyme levels were not elevated. The route of
BG elimination is still unknown. In rabbit models, 80% of the
organ-associated BG was found in the liver and 10% in the kid-
ney. BG was detected in organs, blood and urine at 23%, 18%
and 10%, respectively [21]. Together with the observation that
elimination of BG in dialysis patients takes much longer than in
healthy subjects, this indicates that renal clearance seems to
play some role [15]. However, another study found that the
median plasma half-life of BG in dialysis patients was approxi-
mately 20 h (range 3.1–181.3 h) and was not affected by renal
or hepatic impairment [14]. Therefore, a direct correlation
between high BG levels and impaired renal function is hypo-
thetical, and the reason for our observation remains unclear.
In accordance with the ﬁndings of previous studies, the
diagnostic potential of serum PCR—irrespective of whether
touchdown PCR or real-time PCR was used—is poor, and it
cannot be recommended for the diagnosis of PJP.
In summary, serum BG levels in patients with PJP are
strongly elevated and the negative predictive value is high.
Therefore, measurement of BG could be used as a prelimin-
ary test for patients with suspected PJP before BAL is per-
formed. Neither the outcome nor the pulmonary P. jirovecii
burden seems to correlate with the serum BG level at diag-
nosis or with the peak BG level. Accordingly, the prognostic
value of single BG measurements in PJP is low. BG levels
start to increase up to 21 days before microbiological diag-
nosis, and this could be helpful in reducing the time until
adequate treatment is initiated.
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